Navigation Links
New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility

e of mortality up to 6 months after enrolment.

The primary safety endpoint was major hemorrhagic complications during the same period.

About venous thromboembolism (VTE)

Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE).

VTE is also a common complication among acutely-ill medical patients who have recently been immobilized, a population of medically-ill patients at particularly high-risk for VTE.

About Clexane(R) / Lovenox(R) (enoxaparin)

Lovenox(R) is a unique chemical entity in a class of antithrombotic agents known as low-molecular weight heparin (LMWH). The no. 1 selling low-molecular weight heparin in the world, Lovenox(R) is obtained by alkaline degradation of heparin benzyl ester and is about one-third the molecular size of unfractionated heparin. Lovenox(R) is the most widely studied LMWH, with 20 years of use in the treatment of 185 million patients in 96 countries.

Its clinical applications are linked to its antithrombotic properties. It is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis. As with all anticoagulants, the most frequently reported side effect with Lovenox(R) is bleeding. Clinical indications for Lovenox(R) may vary from one country to another.

About sanofi-aventis

Sanofi-aventis is one of the world's leading pharmaceutical companies, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Inc. (NYSE: LDR) announced today that its Board of ... share for the second quarter of fiscal 2012. The dividend will ... on March 9, 2012. About Landauer ... services to determine occupational and environmental radiation exposure and is ...
... BRUSSELS, Feb. 28, 2012 Eli Lilly and Company (NYSE: ... global Innovation Starts Here initiative which supports Lilly,s commitment to ... the world. Two key components of this ... Innovation Fellowship Awards. Through both, Lilly scientists will collaborate with ...
Cached Medicine Technology:Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 2Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 3Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 4Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 5
(Date:11/21/2014)... Orange County, CA (PRWEB) November 21, 2014 ... be featured in an upcoming episode of Innovations with ... 2015. Dates and show times TBA. , Big Bud ... with information for growing, harvesting, and utilization of medical ... look at Big Bud Farms’ wide variety of products ...
(Date:11/21/2014)... November 21, 2014 Launched today on ... is an all-in-one senior care coordination tool designed to ... ones simple and intuitive for family members and caregivers ... centers). Now, the family caregiver or home health aide ... activities, health data, medical records, goals, schedules, and even ...
(Date:11/21/2014)... November 21, 2014 TruDenta, the creator ... headaches and other jaw-related symptoms, has reported a ... from chronic head pain, neck pain, TMJ (temporomandibular joint) ... year we have seen a 52% increase in the ... of over 300 doctors and their teams in 47 ...
(Date:11/21/2014)... 2014 CDT PLUS! 2015 ... It includes everything needed to process dental insurance claims. ... CDT , CDT 2015 codes are mandatory for reporting ... - December 31, 2014. Dental professionals must use HIPAA ... dental claims. There are significant changes in the CDT ...
(Date:11/21/2014)... November 21, 2014 TopConsumerReviews.com recently ... an industry leader in the relief of ... significant feelings of sadness and depression each year ... pharmaceutical choices. Often, prescription drugs can produce worse ... drugs are expensive and require regular follow-up visits ...
Breaking Medicine News(10 mins):Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Comprehensive Senior Care Application Launched on Apple App Store 2Health News:National Rise In Patients Seeking Headache Relief 2Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2
... New Delhi: The National AIDS Control Organization (NACO) has ... to provide free anti-retroviral treatment (ART). //The count of ... on the anvil. , ,These centers will support ... the services of exclusive doctors, counselors and laboratory technicians ...
... or get the consent of one or both parents before ... to a Florida State University law professor in Tallahassee, Fla. ... and Thomas Stratmann, professor of economics at George Mason University, ... of gonorrhea among teenage girls as a measure of risky ...
... reduce their risk of becoming obese children, even if ... a study led by a researcher at the University ... ,The findings contradict an earlier, smaller study that found ... diabetes had poor glucose tolerance, a precursor to diabetes, ...
... self-image as the “strong, silent type” and the stigma ... less likely than women to be referred to studies ... recognize and express symptoms of depression, according to clinicians ... UC Davis Department of Psychiatry and Behavioral Sciences. ...
... tennis elbow and a wait and watch approach may be ... Australian researchers tested this approach in one group of volunteers, ... ,A second group were given a local ... The final group received eight treatments of physiotherapy of 30 ...
... amphetamine abuse in the Asia-Pacific region has hit high levels ... problem threatening Asia that is this big is a problem ... Australia as is the security of Australia in terms of ... the United Nations Office of Drugs and Crime told AFP. ...
Cached Medicine News:Health News:Abortion Notification, Consent Laws Reduce Risky Teen Sex 2Health News:Breast-Feeding May Reduce Childhood Obesity 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 2Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 3Health News:Stereotypes Contribute to Older Men Seeking, Receiving Depression Care Less Frequently 4Health News:Steroids Ineffective In Tennis Elbow 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: